Maixin Company Profile

Fuzhou Maixin Biotechnology Development Co., Ltd., established in 1993 with a registered capital of 50 million RMB, is located at No. 115-1, Gaoxin Avenue, Shangjie Town, Minhou County, Fujian Province (Fuzhou Maixin Bio-park), postal code 350108. It is a leading Chinese company in immunohistochemical diagnostic reagents for tumor pathology and a high-tech biopharmaceutical enterprise. Its business covers multiple fields including tumor pathology diagnosis, immunocytochemical diagnosis, molecular pathology diagnosis, and precision medicine diagnosis, with a marketing network spanning the entire country.
Maixin was the first domestic company to obtain the NMPA (formerly CFDA) Class III medical device production license for immunohistochemical products and currently holds 52 patents. In 2013, Maixin officially entered the Haixi Industrial Park Innovation Park in Fuzhou High-tech Zone, vigorously promoting the development of key technologies and products to improve the localization level of tumor diagnostic reagents and instruments. In the same year, the company released its independently developed monoclonal antibodies with the “MX” label clone number, which currently number over one hundred. In 2015, the first domestically developed fully automatic immunohistochemical staining system (Titan) was successfully launched. In 2016, the newly developed high-performance molecular pathology diagnostic product RedBright™ FISH probe was launched.
Maixin established China’s first immunohistochemistry quality control laboratory as early as 1999. In 2016, Maixin successfully passed the ISO9001 and ISO13485 audits and certifications. In 2017, the “Maixin Pathology Diagnostic Center” obtained a medical institution practice license, becoming a key project under the Fujian Provincial Government’s “Five Batches” program. At the same time, Maixin participated as a drafting unit in the formulation of the industry standard for “Immunohistochemistry Reagent Kits” and participated in the writing of several domestic pathology academic monographs. The company has always actively participated in industry association/pathology society activities and undertaken many important tasks. The vision of becoming a new type of innovative enterprise with social and industry responsibility has always been the direction of Maixin’s progress. Maixin values ​​brand equity and investment in research and development, and has received widespread recognition from rating agencies and society for its comprehensive strength, corporate management, and social responsibility. It has successively won numerous honors, including “Fujian Provincial Famous Trademark,” “Fujian Provincial Engineering Technology Research Center for Immunopathology Reagents,” “Fujian Provincial Enterprise Technology Center,” “Fujian Provincial Leading Enterprise in Science and Technology,” “(First) Fujian Enterprise ‘Innovation’ 100,” and “Fuzhou High-tech Zone Gazelle Enterprise.”
“With the wind at our backs, we will sail across the vast ocean,” the advancing Maixin will proudly carry the banner of a national brand in pathological diagnosis, steadily moving forward in the IVD in-vitro diagnostic field with its professional, high-quality, and convenient products and services.